India Court Rejects Cancer Drug Patent Bid - Presented by: The Aol. On Network

Residents in India's capital New Delhi form long queues at this pharmacy. The country is home to a drugs market that grows between 13 and 14 percent every year, making it an attractive investment for Western pharmaceutical companies. But a landmark court ruling could change that. On Monday, India's top court rejected a bid by Swiss drug-maker Novartis to win patent protection for its cancer drug, Glivec.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 15.84 0.15 ▼ 0.94%
PBR $ 6.18 0.23 ▼ 3.59%
OREX $ 8.49 0.85 ▲ 11.13%
AA $ 14.59 0.59 ▼ 3.89%
CHK $ 15.49 0.71 ▼ 4.38%
BABA $ 85.49 3.91 ▲ 4.79%
VALE $ 6.88 0.25 ▼ 3.51%
SIRI $ 3.94 0.06 ▼ 1.50%

As of 3/4/2015, 04:15 PM More Most Active

Latest News Headlines

View All Headlines